fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

UCB’s phase IIa study results of Bepranemab in early Alzheimer’s Disease selected for late-breaking symposium at 2024 CTAD Meeting

Written by | 22 Oct 2024

UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild… read more.

AskBio to showcase cutting-edge research on AAV therapies and manufacturing advancements at ESGCT 2024

Written by | 21 Oct 2024

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 11 presentations offering insights into the research and development… read more.

DURECT Corporation to highlight new data on Larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024

Written by | 21 Oct 2024

DURECT Corporation a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce… read more.

Gilead Sciences to Showcase New Findings on HIV, COVID-19, and Viral Hepatitis at IDWeek 2024, Highlighting Advances in Antiviral Research

Written by | 18 Oct 2024

Gilead Sciences, Inc. announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31… read more.

Sanofi Showcases Groundbreaking Beyfortus Data at IDWeek 2024, Highlighting Over 80% Effectiveness in Protecting Infants Against RSV

Written by | 18 Oct 2024

Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of… read more.

Alexion to Present Key Data on Ultomiris and Soliris for gMG at AANEM and MGFA 2024

Written by | 17 Oct 2024

Alexion, AstraZeneca Rare Disease, will present data from its leading generalised myasthenia gravis (gMG) portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and… read more.

Travere Therapeutics to Present Key Data on FILSPARI™ (Sparsentan) in IgA Nephropathy and FSGS at ASN Kidney Week 2024

Written by | 17 Oct 2024

Travere Therapeutics, Inc.,  announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27,… read more.

AstraZeneca Set to Reveal New Data on Immunotherapies and Vaccines at Upcoming IDWeek 2024

Written by | 17 Oct 2024

AstraZeneca will share new data across its Vaccines & Immune Therapies portfolio at the 13th annual IDWeek in Los Angeles, California, from 16-19 October 2024. The Company will highlight… read more.

Plus Therapeutics to Showcase Breakthroughs in CNS Cancer Treatments at SNO/ASCO 2024 Conference

Written by | 25 Jul 2024

Plus Therapeutics,  a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.

Merck to Present New HIV Research and Host Symposia at the 25th International AIDS Conference in Munich

Written by | 22 Jul 2024

Merck, known as MSD outside of the United States and Canada, announced upcoming data presentations and programming at the 25th International AIDS Conference (AIDS 2024), taking place July 22-26,… read more.

Launch of US pharmacy technician society

Written by | 18 Dec 2023

ASHP Midyear Clinical Meeting – Highlights In November 2023 The Pharmacy Technician Society (TPTS) was launched under the wing of The American Society for Health System Pharmacists (ASHP)…. read more.

ISC 2022: After a severe stroke, endovascular therapy may be crucial

Written by | 17 Feb 2022

Following a severe stroke caused by artery-blocking clots, patients who undergo endovascular therapy (mechanical clot removal) plus standard medical therapy have fewer physical limitations 90 days post-stroke compared… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.